Papilledema (Optic Disc Swelling): Causes, Symptoms, Risks, and Treatment

What is Papilledema?

To understand papilledema, it helps to first understand the anatomy involved. The optic disc (also known as the optic papilla or optic nerve head) is the point at the back of the eye where the optic nerve exits the eyeball and carries visual information from the retina to the brain. This small structure is the essential connection between the eye and the visual cortex.

In medicine, edema refers to swelling caused by the abnormal accumulation of fluid in tissues. Papilledema, therefore, specifically describes swelling of the optic disc due to elevated intracranial pressure (ICP), meaning increased pressure within the skull. This distinction is important because not all optic disc swelling is papilledema.

Clinically, papilledema must be differentiated from the broader category of optic disc edema, which can arise from a variety of other conditions, including:

• Intraocular inflammation (for example uveitis or scleritis)
• Central retinal vein occlusion, a blockage of the main retinal venous drainage
• Compressive optic neuropathy, pressure on the optic nerve from a mass lesion such as a tumor
• Optic neuritis, inflammation of the optic nerve often associated with multiple sclerosis
• Diabetic papillopathy, optic disc swelling related to diabetes
• Ischemic optic neuropathy, reduced blood flow leading to optic nerve damage
• Malignant hypertension, severely elevated blood pressure causing end-organ damage including the optic nerve

When used precisely, the term papilledema refers only to optic disc swelling caused by raised intracranial pressure. This distinction is clinically significant because papilledema typically signals a potentially serious underlying neurological condition that requires prompt evaluation.

Why Is Papilledema Clinically Important?

Papilledema is considered a critical neurological sign because it is almost invariably a marker of a serious underlying condition. Among the most important and dangerous causes are:

• Brain tumors can be either primary, meaning they originate in the brain, or secondary, meaning they are metastatic and spread from elsewhere in the body.
• Inflammation of the brain or spinal cord, which includes both infectious causes such as bacterial meningitis and viral encephalitis, as well as non-infectious inflammatory conditions like neurosarcoidosis.
• Idiopathic intracranial hypertension (IIH) is a condition in which intracranial pressure becomes elevated, yet no identifiable structural cause is present. Historically, it has also been called pseudotumor cerebri.

Because it serves as a window into intracranial pathology, fundoscopic examination literally allows clinicians to observe the effects of brain pressure changes through the eye. For this reason, the detection of papilledema during such an exam is always treated as an urgent finding that requires prompt and thorough investigation.

---

Should You Be Worried?

In short: yes, papilledema warrants serious and prompt medical attention, though the ultimate outlook depends heavily on what is causing it.

The prognosis of papilledema is directly tied to the underlying disease responsible for elevated intracranial pressure. When the cause is identified and treated quickly and effectively, the prognosis for vision can be very good. However, when intracranial pressure remains chronically elevated, whether because the underlying cause is not treated or because the condition is inherently difficult to control, the consequences can be severe and permanent.

Chronic, sustained elevation of intracranial pressure causes progressive damage to the retinal nerve fiber layer surrounding the optic disc. As these delicate nerve fibers are progressively compressed and destroyed, patients begin to experience:

• Progressive constriction of the visual field (peripheral vision loss, often beginning with the blind spot enlargement before advancing to tunnel vision)
• Loss of central visual acuity in advanced cases
• Permanent blindness, in the most severe and untreated scenarios

This makes early detection and treatment of papilledema, and crucially its underlying cause, an absolute priority. There is typically a therapeutic window during which treatment can prevent irreversible vision loss, but this window may be narrow depending on the cause and severity of the intracranial hypertension.

The overarching message is that papilledema is never to be dismissed or monitored passively without a clear, active diagnostic and therapeutic plan.

---

Causes

The Mechanism: Why Does Elevated Intracranial Pressure Cause Disc Swelling?

To understand the causes of papilledema, it is essential to understand the mechanism by which raised intracranial pressure leads to optic disc swelling.

The skull is a rigid bony structure with a fixed internal volume. The contents of this space include the brain parenchyma, blood within cerebral vessels, and cerebrospinal fluid (CSF); together, they fill the fixed volume completely. This relationship is described by the Monro-Kellie doctrine: the total volume of the intracranial contents is constant, and if one component increases in volume, at least one of the others must decrease, or intracranial pressure will rise.

If any of these components expand, such as from a growing tumor, excess cerebrospinal fluid, increased blood volume, or cerebral edema, the body’s ability to compensate may be overwhelmed. Once that happens, intracranial pressure will increase. This elevated pressure is transmitted along the subarachnoid space that surrounds the optic nerve all the way to the back of the eye. The elevated pressure impedes axoplasmic transport (the movement of substances along nerve axons) within the nerve fibers of the optic disc, causing fluid to build up and the disc to swell.

Common Causes of Elevated Intracranial Pressure Leading to Papilledema

Papilledema typically develops bilaterally, affecting both eyes, because elevated intracranial pressure affects both optic nerves equally. Asymmetric or unilateral papilledema is rare but documented. The condition is more common in women than in men, and relatively uncommon in children and the elderly compared to working-age adults.

The most clinically significant causes include:

Space-Occupying Lesions

Any mass within the cranial cavity that displaces brain tissue and raises intracranial pressure can cause papilledema. The most important examples include:

• Brain tumors: Both primary brain tumors (e.g., glioblastoma, meningioma, medulloblastoma) and brain metastases from systemic cancers (e.g., lung, breast, melanoma) can progressively enlarge and compress adjacent structures, raising ICP.
• Brain abscesses: Collections of pus within the brain parenchyma, typically resulting from bacterial, fungal, or parasitic infections, can act as space-occupying lesions.
• Intracranial hemorrhage: Bleeding within the skull, whether in the epidural, subdural, subarachnoid, or intraparenchymal compartments, significantly increases intracranial volume and pressure. Common causes include:
  • Traumatic brain injury (e.g., from a fall, motor vehicle accident, or assault)
  • Ruptured cerebral aneurysm causing subarachnoid hemorrhage
  • Hypertensive intracerebral hemorrhage
  • Hemorrhagic transformation of ischemic stroke

Increased Cerebrospinal Fluid Volume

CSF is produced by the choroid plexus within the brain’s ventricles, circulates around the brain and spinal cord, and is reabsorbed into the venous system. Any disruption of this cycle can lead to CSF accumulation and elevated ICP:

• Hydrocephalus: Abnormal accumulation of CSF within the ventricular system, which can result from obstruction of CSF pathways (obstructive hydrocephalus) or impaired reabsorption (communicating hydrocephalus). Common causes include:
  • Meningitis is inflammation of the meninges, the membranes surrounding the brain and spinal cord. It is typically caused by bacterial, viral, or fungal infections and may block cerebrospinal fluid reabsorption.
  • Encephalitis refers to inflammation of the brain parenchyma. It is most commonly caused by a viral infection.
  • Subarachnoid hemorrhage: Blood in the subarachnoid space may obstruct the arachnoid granulations, which are responsible for CSF reabsorption.
  • Congenital malformations (e.g., aqueductal stenosis)

Increased Cerebral Blood Volume

Abnormal expansion of the vascular compartment within the cranium can also raise ICP:

• Cerebral venous sinus thrombosis (CVST): Clotting within the dural venous sinuses, which are the large venous channels draining blood from the brain, impedes venous outflow. This causes venous blood to back up, raising intracranial pressure and leading to cerebral edema and sometimes hemorrhage. CVST is an important cause of papilledema, particularly in young women.
• Idiopathic intracranial hypertension (IIH): This condition, formerly known as pseudotumor cerebri, is characterized by raised ICP in the absence of a structural lesion, hydrocephalus, or secondary cause on neuroimaging, and with a normal CSF composition on lumbar puncture. The exact pathophysiology remains incompletely understood but likely involves impaired CSF reabsorption and increased CSF production.

Risk Factors for Idiopathic Intracranial Hypertension

IIH deserves special mention because it is a relatively common cause of papilledema, particularly in certain demographic groups. Established risk factors include:

• Obesity: IIH has a strong and well-documented association with overweight and obesity, particularly in women of childbearing age. The prevalence of IIH has risen in parallel with global obesity rates. The mechanism is thought to involve increased intra-abdominal pressure, elevated intrathoracic pressure, and impaired venous drainage from the cranium.
• Female sex: IIH is far more common in women than men, with a female-to-male ratio of approximately 9:1 in obese patients.
• Reproductive age: IIH predominantly affects women between the ages of 20 and 50.
• Certain medications: Several drugs have been associated with the development of IIH, including:
  • Corticosteroids, especially when discontinued after prolonged use, can lead to complications.
  • Retinoids (e.g., isotretinoin, used for acne).
  • Tetracycline-class antibiotics (e.g., doxycycline, minocycline).
  • Oral contraceptives (though the evidence here is less conclusive).
  • Vitamin A excess (hypervitaminosis A).
  • Growth hormone supplementation.
  • Lithium.

---

Symptoms

Papilledema itself is often asymptomatic in its early stages, especially when intracranial pressure rises gradually. It is typically discovered incidentally during a fundoscopic examination performed for another reason. However, as pressure rises and the optic disc becomes more swollen, symptoms related to both the disc swelling and the underlying elevated intracranial pressure typically emerge.

Visual Symptoms

Visual disturbances are among the most characteristic manifestations of papilledema and can range from subtle and transient to severe and permanent:

• Blurred vision: One of the earliest and most common visual complaints. It may be mild and intermittent initially, particularly during position changes or Valsalva maneuvers (straining, coughing, sneezing), which transiently increase intracranial pressure.
• Transient visual obscurations (TVOs): Brief episodes of dimming or complete loss of vision in one or both eyes. These typically last only seconds and are often triggered by postural changes, such as standing up quickly, or by Valsalva maneuvers. TVOs are a classic symptom of papilledema and reflect transient ischemia of the optic nerve due to pressure-induced impairment of blood flow.
• Double vision (diplopia): Often caused by compression or stretching of the sixth cranial nerve (abducens nerve), which has the longest intracranial course of any cranial nerve and is therefore particularly vulnerable to raised ICP. This results in horizontal diplopia due to lateral rectus palsy, which is an inability to fully abduct the eye. It is considered a “false localizing sign” because it reflects raised intracranial pressure generally rather than a lesion specifically affecting the sixth nerve.
• Loss of peripheral (side) vision: As papilledema progresses and nerve fiber damage accumulates, patients develop progressive constriction of their visual field. An early and characteristic finding on visual field testing is enlargement of the blind spot (the area with no photoreceptors, corresponding to the optic disc), followed by progressive loss of peripheral visual field if pressure is not controlled.
• Loss of central visual acuity: A late and ominous development indicating advanced, severe, or long-standing nerve fiber damage.
• Color vision disturbances: Reduced color saturation or discriminability may also be an early sign.

Headache

Headache is the most common symptom of raised intracranial pressure and is present in the vast majority of patients with papilledema. It has several characteristic features:

• Worse in the morning (due to increased ICP during recumbency and overnight hypoventilation causing CO₂ retention, which is a potent cerebral vasodilator)
• Exacerbated by Valsalva maneuvers, such as coughing, sneezing, or straining at stool.
• Positional component: symptoms worsen when lying flat but improve somewhat when sitting or standing.
• Diffuse or generalized in distribution.
• Pulsating or pressure-like in quality.

In IIH, headache is typically the most prominent and disabling symptom. Patients often describe it as a constant, pressure-like pain that worsens in the morning and with position changes. It may also be associated with pulsatile tinnitus, a whooshing sound in the ears that occurs in sync with the heartbeat. This is a distinctive symptom of IIH, caused by turbulent venous flow.

Nausea and Vomiting

Nausea and vomiting are common accompanying symptoms, particularly when ICP is acutely and markedly elevated. This is of central origin, meaning it arises from direct stimulation of vomiting centers in the brainstem by raised intracranial pressure, rather than from any primary gastrointestinal cause. Characteristically, the vomiting may be projectile (sudden, forceful, and without preceding nausea) in acute severe intracranial hypertension.

Absence of Eye Pain

It is important to note that papilledema is typically painless; there is generally no localized pain in or around the eye itself. This distinguishes it clinically from conditions such as optic neuritis (where eye pain, especially with movement, is very common) or acute angle-closure glaucoma (which causes severe eye pain). The absence of pain can unfortunately lead some patients (and occasionally clinicians) to underestimate the seriousness of visual symptoms in the context of papilledema.

Other Associated Symptoms

Depending on the underlying cause of elevated ICP, additional neurological symptoms may be present:

• Altered consciousness or confusion: Particularly in severe or acute elevation of ICP
• Focal neurological deficits: Such as limb weakness, speech difficulties, or coordination problems (suggesting a structural brain lesion)
• Seizures: May occur with cortical irritation from a tumor, abscess, or hemorrhage
• Neck stiffness and photophobia: Suggestive of meningeal irritation (meningitis or subarachnoid hemorrhage)
• Pulsatile tinnitus: Characteristic of IIH
• Memory or cognitive difficulties: In chronic IIH or with large lesions affecting frontal lobes

---

Diagnosis

The diagnosis of papilledema is primarily clinical, as it relies on direct visualization of the optic disc. However, the critical and urgent question remains: What is causing the elevated intracranial pressure? Because of this, the workup focuses on identifying or ruling out serious underlying conditions.

Ophthalmoscopic Examination (Fundoscopy)

The cornerstone of papilledema diagnosis is the fundoscopic examination, which involves examining the fundus oculi (the back of the eye). This procedure is performed by an ophthalmologist, neurologist, or trained emergency physician using an ophthalmoscope or slit-lamp biomicroscopy. This allows direct visualization of the optic disc and the surrounding retina.

The Frisén grading scale is the most widely used system for grading papilledema severity, ranging from:

• Grade 0: Normal optic disc.
• Grade 1: Very early papyledema, showing subtle blurring of the nasal disc margin.
• Grade 2: Early papilledema. Here, you’ll notice obscuration of the disc margins and the beginning of elevation.
• Grade 3: Moderate papilledema. This involves obscuration of a major blood vessel leaving the disc.
• Grade 4: Marked papilledema, which involves the complete obscuration of a segment of a major blood vessel on the disc.
• Grade 5: Severe papilledema, with complete obscuration of all vessels on the disc.

Characteristic fundoscopic findings of papilledema include:

• Blurring and elevation of the disc margins (the disc appears raised above the surrounding retinal surface)
• Engorgement of retinal veins and loss of the normal venous pulsations
• Flame-shaped hemorrhages around the disc margins
• Cotton wool spots (areas of superficial retinal ischemia)
• Macular exudates in severe cases (producing a characteristic “star” pattern)

Optical Coherence Tomography (OCT)

OCT of the retinal nerve fiber layer (RNFL) has become an invaluable tool in the management of papilledema. This non-invasive, high-resolution imaging technique allows precise, quantitative measurement of the thickness of the RNFL surrounding the optic disc, enabling:

• Objective grading of disc swelling severity
• Longitudinal monitoring of response to treatment
• Detection of early nerve fiber loss (which may signal progressive damage despite control of ICP)

Neuroimaging

Once papilledema is detected, urgent neuroimaging is mandatory to look for structural causes of raised ICP before performing a lumbar puncture (to avoid the risk of cerebral herniation if a mass lesion is present).

• Magnetic Resonance Imaging (MRI) of the brain with and without gadolinium contrast is the preferred modality. It provides superior soft tissue resolution and can identify:

  • Brain tumors (primary and metastatic)
  • Abscess
  • Hemorrhage
  • Hydrocephalus
  • Cerebral edema
  • Signs of raised ICP, such as flattening of the posterior sclera, empty sella turcica, tortuous optic nerve sheaths with prominent perineural CSF spaces, or transverse sinus stenosis (findings particularly associated with IIH), can include the following.

• CT scan of the brain may be performed as a more rapidly available alternative, particularly in emergency settings, before MRI can be obtained.

• MR venography (MRV) or CT venography: Specifically indicated when cerebral venous sinus thrombosis is suspected as the cause of elevated ICP.

Lumbar Puncture (Spinal Tap)

Once a space-occupying lesion has been excluded by neuroimaging, lumbar puncture is performed to:

• Measure opening CSF pressure directly (the definitive test for confirming elevated ICP; a pressure >25 cmH₂O in a relaxed lateral decubitus position is generally considered elevated)
• Analyze CSF composition, including cell count, protein, glucose, cultures, and cytology, to identify meningitis, encephalitis, carcinomatous meningitis, or other CSF abnormalities.

In IIH, the CSF pressure is elevated, yet the CSF composition remains entirely normal. This distinction is one of the key diagnostic criteria for the condition.

Additional Investigations

Depending on the clinical context, further investigations may include:

• Formal visual field testing (perimetry): Essential for quantifying and monitoring the extent of visual field loss attributable to optic nerve damage. This is one of the most important outcomes to monitor over time in patients with papilledema.
• Blood tests: Including complete blood count, inflammatory markers (CRP, ESR), autoimmune antibodies, hormonal profiles, vitamin levels, and blood cultures where indicated
• Angiography (cerebral or retinal): In selected cases to evaluate for vascular malformations, vasculitis, or to better characterize cerebral venous anatomy

---

Treatment

The treatment of papilledema is fundamentally the treatment of its underlying cause. There is no specific therapy for the disc swelling itself. Instead, the goal is to reduce intracranial pressure and protect the optic nerves from permanent damage. Alongside causal treatment, close ophthalmological monitoring of visual function is essential throughout management.

Treating the Underlying Cause

Brain Tumors and Other Space-Occupying Lesions

When a mass lesion (tumor, abscess, hematoma) is responsible for raised ICP, neurosurgical intervention is typically the primary treatment. Options depend on the nature and location of the lesion and may include:

• Surgical resection of accessible tumors
• Stereotactic radiosurgery (e.g., Gamma Knife, CyberKnife) for small or surgically inaccessible lesions
• Radiotherapy and/or chemotherapy for malignant tumors
• Surgical drainage of abscesses
• Evacuation of hematomas

Glucocorticoids (e.g., dexamethasone) are frequently used perioperatively to reduce cerebral edema surrounding tumors, providing temporary relief of elevated ICP while awaiting definitive surgical or oncological treatment.

Hydrocephalus

• Ventriculoperitoneal (VP) shunt or ventriculoatrial (VA) shunt: Surgical insertion of a shunt system that diverts excess CSF from the cerebral ventricles to the peritoneal cavity or right atrium, respectively
• Endoscopic third ventriculostomy (ETV): A minimally invasive surgical procedure that creates an alternative drainage pathway for CSF, avoiding the need for a permanent shunt in selected cases

Meningitis and Encephalitis

• Appropriate antimicrobial, antiviral, or antifungal treatment depending on the causative organism
• Adjunctive dexamethasone in bacterial meningitis (particularly pneumococcal) has been shown to reduce neurological complications and mortality

Cerebral Venous Sinus Thrombosis (CVST)

• Anticoagulation with low molecular weight heparin (LMWH) followed by oral anticoagulants (warfarin or direct oral anticoagulants) is the standard treatment, aiming to recanalize the thrombosed sinus, reduce venous hypertension, and prevent thrombosis extension
• In severe or refractory cases, endovascular thrombectomy or local thrombolysis may be considered

Treatment of Idiopathic Intracranial Hypertension (IIH)

IIH management is multifaceted and requires close collaboration between ophthalmology and neurology:

Weight Loss

In obese patients with IIH, weight loss is the single most effective intervention and can lead to complete resolution of symptoms and normalization of ICP. Even a modest weight reduction of 5–10% of body weight has been shown to produce significant improvement. Structured weight loss programs, very low-calorie diets, and bariatric surgery have all been studied in this context, with bariatric surgery showing the most dramatic and durable results in severely obese patients.

Acetazolamide

Acetazolamide is the first-line pharmacological treatment for IIH. It is a carbonic anhydrase inhibitor that reduces CSF production by the choroid plexus, thereby lowering ICP. The landmark Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) demonstrated that acetazolamide combined with weight loss was superior to weight loss alone in improving visual field outcomes. Common side effects include:

• Paresthesias (tingling, particularly in the fingers and toes)
• Dysgeusia (metallic taste)
• Fatigue
• Nausea
• Kidney stones (with long-term use)

Dosing typically starts low and is titrated upward based on efficacy and tolerability.

Other Medical Options

• Topiramate: An anticonvulsant with weak carbonic anhydrase inhibitory activity that may also promote weight loss, making it a useful alternative or adjunct to acetazolamide
• Furosemide or other diuretics: Occasionally used in combination with acetazolamide
• Serial lumbar punctures: May provide temporary relief of symptoms and are sometimes used as a bridge to other treatments, particularly during pregnancy (when medications may be contraindicated)

Surgical Interventions for Vision Protection

When medical therapy fails to prevent progressive visual loss, or when patients present with severe visual impairment that threatens permanent blindness, surgical options must be considered urgently.

• Optic nerve sheath fenestration (ONSF): A surgical procedure in which small windows (fenestrations) are cut in the meningeal sheath surrounding the optic nerve, just behind the eye. This allows excess CSF to drain away from the optic nerve head, decompressing it and protecting the nerve from further pressure-induced damage. ONSF is particularly effective for visual preservation but has less consistent effects on headache.

• CSF diversion surgery (shunting):

  • Lumboperitoneal (LP) shunt: Diverts CSF from the lumbar subarachnoid space to the peritoneal cavity
  • Ventriculoperitoneal (VP) shunt: An alternative when LP shunting is not feasible

  Shunt procedures address the systemic ICP elevation and can therefore improve both visual symptoms and headache, but are associated with a significant risk of shunt malfunction and revision surgery.

• Venous sinus stenting: An emerging endovascular procedure in which a stent is placed within a stenosed dural venous sinus (most commonly the transverse sinus, stenosis of which has been identified as a contributor to elevated ICP in many IIH patients). Preliminary evidence suggests this procedure can effectively reduce ICP and improve symptoms in carefully selected patients, but long-term data are still accumulating.

Monitoring and Follow-Up

Regardless of the treatment approach, patients with papilledema require regular, ongoing ophthalmological monitoring to track:

• Visual acuity
• Color vision
• Visual fields (formal perimetry at regular intervals)
• Optic disc appearance on fundoscopy
• RNFL thickness on OCT

The goal is to detect any progression of optic nerve damage at the earliest possible stage, allowing treatment to be escalated before permanent visual loss occurs. The frequency of monitoring depends on the severity of papilledema and the stability of the underlying condition.

---

A Summary: Key Points About Papilledema

To consolidate the essential clinical take-aways from this article:

1. Papilledema refers to swelling of the optic disc, caused specifically by elevated intracranial pressure. It is not simply any form of optic disc edema.
2. It is almost always a sign of a serious underlying condition, such as a brain tumor, intracranial hemorrhage, hydrocephalus, meningitis, venous sinus thrombosis, or idiopathic intracranial hypertension.
3. It typically affects both eyes, though asymmetric involvement is possible.
4. Key symptoms include transient visual obscurations, blurred vision, visual field loss, double vision, and headache. Notably, eye pain is usually absent.
5. Diagnosis begins with fundoscopy and must be followed urgently by neuroimaging and, when appropriate, lumbar puncture.
6. Treatment is directed at the underlying cause: surgery for tumors, anticoagulation for venous thrombosis, and acetazolamide and weight loss for IIH.
7. Surgical procedures (optic nerve sheath fenestration, CSF shunting) are reserved for cases where vision is severely threatened despite medical management.
8. Chronic elevated ICP can cause permanent blindness. Early detection and treatment are essential to preserve vision.

---

Sources and Bibliography

• Papilledema: Rupak Dhoot; Edward Margolin
• Wall M, Kupersmith MJ, Kieburtz KD, et al. The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline. JAMA Neurology. 2014;71(6):693-701.
• Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(10):1088-1100.
• Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165.
• Hayreh SS. Pathogenesis of optic disc edema in raised intracranial pressure. Progress in Retinal and Eye Research. 2016;50:108-144.
• Biousse V, Newman NJ. Ischemic optic neuropathies. New England Journal of Medicine. 2015;372(25):2428-2436.
• Lenck S, Vallée F, Labeyrie MA, et al. Stenting of the lateral sinus in idiopathic intracranial hypertension according to the type of stenosis. Neurosurgery. 2017;80(3):393-400.
• Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.
• Thurtell MJ, Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Current Treatment Options in Neurology. 2013;15(1):1-12.
• Ball AK, Clarke CE. Idiopathic intracranial hypertension. Lancet Neurology. 2006;5(5):433-442.
• Brodsky MC, Vaphiades M. Magnetic resonance imaging in pseudotumor cerebri. Ophthalmology. 1998;105(9):1686-1693.